Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 26, 2021
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
[ Mon, Apr 26th 2021
] - WOPRAI
Robert Burns Maintained (ADCT) at Strong Buy with Increased Target to $57 on, Apr 26th, 2021
Robert Burns of HC Wainwright & Co., Maintained "ADC Therapeutics SA" (ADCT) at Strong Buy with Increased Target from $48 to $57 on, Apr 26th, 2021.
Robert has made no other calls on ADCT in the last 4 months.
There is 1 other peer that has a rating on ADCT. Out of the 1 peers that are also analyzing ADCT, 0 agree with Robert's Rating of Hold.
This is the rating of the analyst that currently disagrees with Robert
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $55 on, Tuesday, March 23rd, 2021
